Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference15 articles.
1. US Food and Drug Administration. Guidance and regulation. http://www.fda.gov/Food/GuidanceRegulation. Accessed December 9, 2014.
2. Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36 (suppl 2):S253–S258.
3. US Food and Drug Administration. Economic impact analyses of FDA regulations. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/. Accessed December 9, 2014.
4. Bouvy J, Koopmanschap M, Shah R, Schellekens H. The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther. 2012;91 (2):281–288.
5. Pasquali S, Lam W, Chiswell K, Kemper A, Li J. Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov Registry. Pediatrics. 2012;130 (5):e1269–e1277.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献